Browse studies

Find your next paid study

26 recruiting studies matching your filters

A Phase I Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

The purpose of this study is to evaluate the safety, tolerability, and efficacy of combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control…

HIV-1-infection

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT06987318

Observational

Addressing Barriers to Anti-hypertensive Medication Adherence Among Persons Living With HIV Who Have Achieved Viral Suppression

Among those with hypertension, persons living with HIV (PWH) have a 50% higher risk of incident myocardial infarction compared to the general population, and t…

HypertensionHIV-1-infection

Estimated

~$10 – $6,250

Duke UniversityNCT05459077

Phase 2

A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV-1

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (…

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07266831

Phase 2

An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1

The study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B. The goal of Phase 2, Part A is to assess the effe…

HIV-1-infection

Estimated

~$10 – $7,500

Gilead SciencesNCT07708727

Phase 2

ImproviNg Coronary Vascular Health in Women With Risk Factors fOR Myocardial Infarction Type 2 (INFORM-2)

Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the i…

HIV-1-infectionCoronary Microvascular DysfunctionMetabolic Disease

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06843902

Phase 2

A Phase 2 Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1

The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus…

HIV-1-infection

Estimated

~$10 – $7,500

Gilead SciencesNCT07645287

Phase 1

Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.4…

HIV-1

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT06517693

Phase 1

IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study of the Safety, Tolerability and Pharmacokinetics of IAP086 in Persons With HIV-1 on Antiretroviral Therapy

Purpose: To assess the safety and tolerability of a single dose of IAP086 in persons with HIV suppressed on stable ART Participants: 30 people from UNC within …

HIV-1-infection

Estimated

~$10 – $6,250

University of North Carolina, Chapel HillNCT07596888

Phase 3

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

The goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinl…

HIV-1-infection

Estimated

~$10 – $7,500

Gilead SciencesNCT07683000

Phase 2

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and…

HIV-1-infectionFrailtyImpaired Physical Function+2 more

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06554717

Phase 1

A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus mod…

HIV-1-infection

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT06071767

Phase 1

Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivi…

HIV-1-infection

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT05660980